AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A
Year: 2020
Type: conference-abstract
Authors: Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat, Michael J. Thirman, Jacqueline S. Garcia, Andrew H. Wei, Hartmut Döhner, Pierre Fenaux, Christian Recher, Marina Konopleva, Walter Fiedler, Elisabeth Koller, Violaine Havelange, Andre C. Schuh, Jordi Esteve, Jianxiang Wang, Radovan Vrhovac, Roman Hajek, Kimmo Porkka, Arpad Illes, Ofir Wolach, Attilio Olivieri, Kazuhito Yamamoto, Jun-Ho Jang, Gunnar Juliusson, Vladimir Vorobyev, Su-Peng Yeh, Muhit Ozcan, Wan-Jen Hong, Ying Zhou, Jalaja Potluri, Keith W. Pratz
Institutions: The University of Texas MD Anderson Cancer Center, University of California Davis Medical Center, University of California, Davis, City Of Hope National Medical Center, City of Hope, University of Chicago, University of Chicago Medical Center, Harvard University, Dana-Farber Cancer Institute, The Alfred Hospital, Monash University, University Hospital Ulm, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Centre Hospitalier Universitaire de Toulouse, University Medical Center Hamburg-Eppendorf, Hanusch Hospital, Cliniques Universitaires Saint-Luc, Princess Margaret Cancer Centre, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, University Hospital Centre Zagreb, University Hospital Ostrava, University of Helsinki, Helsinki University Hospital, University of Debrecen, Tel Aviv University, Rabin Medical Center, Aichi Cancer Center, Samsung Medical Center, Sungkyunkwan University, Skåne University Hospital, Botkin Hospital, City Clinical Hospital, China Medical University Hospital, Ankara University, Genentech, AbbVie (United States), Abramson Cancer Center, University of Pennsylvania
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: venetoclax, azacitidine, acute myeloid leukemia, elderly patients, treatment-naive patients, combination therapy, overall survival, complete remission, event-free survival, transfusion independence, cytogenetic risk, comorbidities, first-line therapy, relapse after allogeneic stem cell transplantation, relapse after chemotherapy
Open Access status: closed
OpenAlex ID: W3112464179
